Stephen L. Rawlings

Array ( [id] => 8909624 [patent_doc_number] => 08481687 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-07-09 [patent_title] => 'Anti-ErbB3 antibodies' [patent_app_type] => utility [patent_app_number] => 13/082852 [patent_app_country] => US [patent_app_date] => 2011-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 30 [patent_no_of_words] => 33271 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13082852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7663961 [patent_doc_number] => 20110313230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-22 [patent_title] => 'SPECIFIC BINDING PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/078764 [patent_app_country] => US [patent_app_date] => 2011-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 162 [patent_figures_cnt] => 162 [patent_no_of_words] => 85871 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13078764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9827936 [patent_doc_number] => 08937164 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-20 [patent_title] => 'Biological materials related to CXCR7' [patent_app_type] => utility [patent_app_number] => 13/073044 [patent_app_country] => US [patent_app_date] => 2011-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 41206 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13073044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182197 [patent_doc_number] => 10106600 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Bispecific antibodies [patent_app_type] => utility [patent_app_number] => 13/070582 [patent_app_country] => US [patent_app_date] => 2011-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 22451 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13070582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7499482 [patent_doc_number] => 20110262454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-27 [patent_title] => 'NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 13/069705 [patent_app_country] => US [patent_app_date] => 2011-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 33057 [patent_no_of_claims] => 79 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0262/20110262454.pdf [firstpage_image] =>[orig_patent_app_number] => 13069705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10534908 [patent_doc_number] => 09260529 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-16 [patent_title] => 'Molecules that bind CD180, compositions and methods of use' [patent_app_type] => utility [patent_app_number] => 13/034144 [patent_app_country] => US [patent_app_date] => 2011-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 16 [patent_no_of_words] => 18637 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13034144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6046678 [patent_doc_number] => 20110206675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-25 [patent_title] => 'ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES' [patent_app_type] => utility [patent_app_number] => 13/033500 [patent_app_country] => US [patent_app_date] => 2011-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 25026 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0206/20110206675.pdf [firstpage_image] =>[orig_patent_app_number] => 13033500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6167240 [patent_doc_number] => 20110195915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-11 [patent_title] => 'Method of inhibiting prostate cancer cell proliferation' [patent_app_type] => utility [patent_app_number] => 12/929745 [patent_app_country] => US [patent_app_date] => 2011-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10099 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0195/20110195915.pdf [firstpage_image] =>[orig_patent_app_number] => 12929745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6014821 [patent_doc_number] => 20110223155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-15 [patent_title] => 'ANTAGONIST ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE PREVENTION AND TREATMENT OF NOTCH3-RELATED DISEASES' [patent_app_type] => utility [patent_app_number] => 13/023128 [patent_app_country] => US [patent_app_date] => 2011-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 29650 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0223/20110223155.pdf [firstpage_image] =>[orig_patent_app_number] => 13023128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6110290 [patent_doc_number] => 20110189178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-04 [patent_title] => 'Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions' [patent_app_type] => utility [patent_app_number] => 13/021638 [patent_app_country] => US [patent_app_date] => 2011-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 23328 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0189/20110189178.pdf [firstpage_image] =>[orig_patent_app_number] => 13021638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4623815 [patent_doc_number] => 08003110 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2011-08-23 [patent_title] => 'Metalloproteinase oligopeptides and their therapeutic use' [patent_app_type] => utility [patent_app_number] => 13/012769 [patent_app_country] => US [patent_app_date] => 2011-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 5633 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/003/08003110.pdf [firstpage_image] =>[orig_patent_app_number] => 13012769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7724158 [patent_doc_number] => 08097428 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-01-17 [patent_title] => 'Monoclonal antibodies and their use' [patent_app_type] => utility [patent_app_number] => 13/010737 [patent_app_country] => US [patent_app_date] => 2011-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 33693 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/097/08097428.pdf [firstpage_image] =>[orig_patent_app_number] => 13010737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6187544 [patent_doc_number] => 20110171126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-14 [patent_title] => 'Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma' [patent_app_type] => utility [patent_app_number] => 13/004349 [patent_app_country] => US [patent_app_date] => 2011-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 27535 [patent_no_of_claims] => 60 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0171/20110171126.pdf [firstpage_image] =>[orig_patent_app_number] => 13004349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8767060 [patent_doc_number] => 20130095097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-18 [patent_title] => 'Polypeptide Heterodimers and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 13/519740 [patent_app_country] => US [patent_app_date] => 2010-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 39507 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13519740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8612862 [patent_doc_number] => 20130018174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-17 [patent_title] => 'POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS' [patent_app_type] => utility [patent_app_number] => 13/518861 [patent_app_country] => US [patent_app_date] => 2010-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 33345 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13518861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8701157 [patent_doc_number] => 08394376 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-03-12 [patent_title] => 'Therapeutic agents for alzheimer\'s disease and cancer' [patent_app_type] => utility [patent_app_number] => 12/962019 [patent_app_country] => US [patent_app_date] => 2010-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 24 [patent_no_of_words] => 14336 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12962019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7987213 [patent_doc_number] => 08075900 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-12-13 [patent_title] => 'Melanoma associated peptide analogues and vaccines against melanoma' [patent_app_type] => utility [patent_app_number] => 12/961217 [patent_app_country] => US [patent_app_date] => 2010-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10981 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/075/08075900.pdf [firstpage_image] =>[orig_patent_app_number] => 12961217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10560722 [patent_doc_number] => 09284378 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-15 [patent_title] => 'Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof' [patent_app_type] => utility [patent_app_number] => 12/960407 [patent_app_country] => US [patent_app_date] => 2010-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 88 [patent_no_of_words] => 61375 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12960407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9582456 [patent_doc_number] => 08772459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-07-08 [patent_title] => 'J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use' [patent_app_type] => utility [patent_app_number] => 12/959340 [patent_app_country] => US [patent_app_date] => 2010-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 27 [patent_no_of_words] => 15476 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12959340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7997041 [patent_doc_number] => 08080368 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-12-20 [patent_title] => 'Compositions and methods for the identification, assessment, prevention and therapy of human cancers' [patent_app_type] => utility [patent_app_number] => 12/956500 [patent_app_country] => US [patent_app_date] => 2010-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34694 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 247 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/080/08080368.pdf [firstpage_image] =>[orig_patent_app_number] => 12956500 [rel_patent_id] =>[rel_patent_doc_number] =>)